Long-term follow-up of S0221 (median 12.1 years) in high-risk early breast cancer: weekly vs 2-weekly schedules of doxorubicin-cyclophosphamide and of paclitaxel showed no significant differences in disease-free or overall survival.
RCTn = 3,294 patients
Ali et al. Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer